Company Overview of Druggability Technologies Holdings Limited
Druggability Technologies Holdings Limited, through its subsidiaries, develops and commercializes NanoActive, its proprietary high throughput technology platform. The company also develops nano formulations with improvements and clinically meaningful benefits over original drug formulations. The company was incorporated in 2011 and is based in Dublin, Ireland.
Key Executives for Druggability Technologies Holdings Limited
Compensation as of Fiscal Year 2017.
Druggability Technologies Holdings Limited Key Developments
Druggability Technologies Holdings Ltd Announces Results of Phase I study of DRGT18-2
Oct 5 17
Druggability Technologies Holdings Ltd. announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA. Sirolimus, as developed by Pfizer and approved by the FDA, initially failed to achieve sufficient therapeutic effect in clinical practice due to adverse effects in patients undergoing treatment for prophylaxis of organ rejection receiving renal transplants. Sirolimus has unfavorable PK properties including low bioavailability and high patient variability. These can be major limitations of its therapeutic utility. As an immunosuppressant, organ rejection shows correlation with low Sirolimus blood levels; and toxicity attributed to over-exposure can often lead to discontinuation. The drug shows positive therapeutic effect in mTOR-responsive malignancies, yet it may not be possible to reach the necessary therapeutic exposure safely and reliably with Rapamune®. This lead DRGT to the development and application of the company’s Super-API drug development platform to the Sirolimus drug. Phase 1 study results utilizing the new DRGT18-2 formulations may improve patient outcomes by demonstrating a two-fold improvement in therapeutic bioavailability versus patients receiving Sirolimus in clinical practice. Combined with improved bioavailability there was also a substantial reduction in patient variability over the dosage range tested, 0.5 mg to 40 mg.
Druggability Technologies Holdings Limited Announces Results from Phase I Pain Programs
Dec 19 16
Druggability Technologies Holdings Ltd. has announced the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions of Celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug, or NSAID. There are many treatment options for pain. Traditional NSAIDs (e.g.; ibuprofen, naproxen) are nonselective - they inhibit both COX-1 and COX-2. The inhibition of COX-2 accounts for pain relief and anti-inflammatory effects, whilst the inhibition of COX-1 can lead to toxicity and associated side effects (ulcers, prolonged bleeding time, kidney problems). Celecoxib is the only COX-2 inhibitor on the market. It is used to treat pain and inflammation, however its use in pain management is limited by a long "kick in" time as a pain killer (50 mins - 1.5 hours) even at the highest (400mg) dose.DRGT-46 (200 mg) and DRGT-47 (100 mg), novel Super-API compositions were developed by DRGT as new fast and flexible treatment options for acute and chronic pain. In a Phase I clinical study DRGT-46 and DRGT-47 showed very rapid absorption and the opportunity for immediate pain relief. The published effective concentration for onset of action (Ceff =250 ng/ml) was reached within 12 minutes at both doses (100 and 200 mg); under both fasted and fed (high fat) conditions.
DRGT Announces Dr. Philip Kantoff as Senior Clinical Advisor
Dec 14 16
DRGT has announced that Dr. Philip Kantoff has joined the leadership as Senior Clinical Advisor to accelerate the progress of its ambitious oncology drug development program. Dr. Kantoff is the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York. He also served as Director of The Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. He is a Professor Emeritus of Medicine at Harvard Medical School, the Chairman of the Global Treatment Science Network of the Prostate Cancer Foundation, and member of numerous professional societies and editorial boards. Dr. Kantoff published more than 350 research articles on a variety of topics, written nearly 100 reviews and monographs on cancer and has edited numerous books, including Prostate Cancer, A Multi-Disciplinary Guide published by Blackwell, and Prostate Cancer: Principles and Practice, a definitive text on prostate cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|